Filing summary
Entity and period: The supplied filing is Leap Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2017, filed November 13, 2017. This does not match the request metadata naming Cypherpunk Technologies Inc. The company is a clinical-stage biopharmaceutical developer; it reported no product revenue and its candidates were investigational.
Financial results and liquidity
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Research and development expense | $6.802 million | $5.659 million | $18.087 million | $15.870 million |
| General and administrative expense | $1.780 million | $1.369 million | $7.719 million | $3.495 million |
| Net loss | $6.815 million | $7.277 million | $23.134 million | $19.901 million |
| Net loss per share | $0.73 | Not presented | $2.72 | Not presented |
| Operating cash used | Not stated for quarter | Not stated for quarter | $15.768 million | $18.040 million |
At September 30, 2017, cash and cash equivalents were $14.203 million, current assets $16.501 million, current liabilities $5.994 million, and stockholders’ equity $11.585 million. The company reported no outstanding notes payable at quarter-end; $31.145 million of related-party notes and accrued interest had converted to common stock in January 2017. No gross margin is meaningful or reported because there were no product sales.
Nine-month financing cash flow was $29.868 million, including $21.165 million related to the Macrocure merger and $10.0 million from a common-stock sale, partly offset by $2.067 million of deferred offering-cost payments. Cash increased by $13.410 million over the nine-month period, ending at $14.203 million. The filing states that cash decreased by $2.968 million during Q3.
Changes versus comparable periods
- Q3 operating expenses rose $1.554 million year over year, with R&D up $1.143 million and G&A up $0.411 million. Q3 net loss improved by $0.462 million, helped by Australian R&D incentive income, foreign-currency gains, and no related-party interest expense.
- For the nine months, operating expenses increased $6.441 million and net loss widened $3.233 million. Higher stock-based compensation, clinical-trial costs, headcount and public-company costs contributed to expense growth.
- The January 2017 Macrocure transaction, public listing, $10 million stock subscription and conversion of preferred stock and related-party notes materially changed the company’s capital structure. The merger issued 3.257 million shares; common shares outstanding were 9,395,920 at September 30.
Outlook, commentary and risks
- Management expected R&D and G&A expenses to increase as it advanced DKN-01 and TRX518 and operated as a public company. Further financing or collaboration funding was expected to be needed; the filing gives no specific revenue, earnings, cash-runway or financing guidance.
- Management concluded that substantial doubt existed about the company’s ability to continue as a going concern for one year after issuance of the financial statements. Without additional funding or cost-sharing, it might delay, reduce or eliminate trials and other programs.
- Reported clinical updates included a 26% partial-response rate for DKN-01 plus paclitaxel in an esophagogastric cancer study; response rates differed by prior taxane experience. In a TRX518 monotherapy expansion cohort, 50% had stable disease as of August 31, 2017. These are interim investigational results, not evidence of regulatory approval or established efficacy.
- In October 2017, Australia issued a favorable ruling on eligibility of certain overseas R&D activities; the company recognized related incentive income in Q3 for prior-period activity. R&D incentive income was $0.961 million for Q3 and $1.852 million for nine months. The nine-month result also included $0.823 million in foreign-currency gains.
- Manufacturing agreements carried $3.267 million of noncancelable commitments at quarter-end. A royalty agreement requires payments on net sales of TRX518 products (5%) and DKN-01 products (2%) for an indefinite, non-terminable term. European patent opposition proceedings affecting TRX518 remained pending.
Investor verification points
- Confirm the intended issuer: the filing is for Leap Therapeutics, Inc., not Cypherpunk Technologies Inc.
- Assess financing needs and going-concern risk against cash burn, trial plans and available funding; the filing does not provide a definitive cash-runway estimate.
- Review the status and full context of DKN-01 and TRX518 trials, including the limitations of interim clinical data and the absence of regulatory approval.
- Verify the sustainability and collection of Australian R&D incentives, including the impact of the October 2017 eligibility ruling.
- Review the ongoing product royalty obligations, manufacturing commitments and TRX518 patent opposition risks.